Colin Devinant

Collaborateur

Paris + 33.1.56.59.38.71

Colin Devinant possède plus de dix ans d’expérience dans la conduite de contentieux de brevets complexes et à forts enjeux, en France et à l’échelle européenne. Distingué par The Legal 500 depuis 2024, d’abord comme Rising Star puis comme Leading Associate en contentieux de brevets, ainsi que par Best Lawyers comme One to Watch en 2026, Colin représente des entreprises françaises et internationales devant les juridictions françaises et la Juridiction unifiée du brevet (JUB). Habilité à représenter les parties devant la JUB, il intervient régulièrement dans des contentieux paneuropéens et multijuridictionnels, notamment devant les divisions locales françaises et allemandes de la JUB.

Colin joue un rôle de premier plan dans la définition de la stratégie contentieuse et la gestion de litiges portant notamment sur la contrefaçon, la validité des brevets, les mesures d’interdiction provisoire, les saisies et l’évaluation des dommages-intérêts. Il intervient aussi bien pour des titulaires de brevets que pour des entreprises mises en cause, de start-up à des groupes multinationaux, et possède une expérience de la coordination de procédures parallèles dans plusieurs juridictions européennes et aux États-Unis. Sa pratique couvre de nombreux secteurs technologiques, notamment la pharmacie et les biotechnologies, l’électronique et les télécommunications, les logiciels, la chimie et la mécanique.

Sa pratique s’étend également au contentieux et à la protection des secrets d’affaires, ainsi qu’à la rédaction et à la négociation d’accords de confidentialité, de licence, de recherche et de transfert de technologie.

Avant de rejoindre Jones Day en 2018, Colin a pratiqué le contentieux des brevets chez Dechert et Véron & Associés.

Colin publie et intervient régulièrement sur le contentieux des brevets et la JUB. Il est membre du comité directeur du groupe français de l’AIPPI et contribue activement à ses commissions Brevets, JUB et Secrets d’affaires. Il participe également à Young EPLAW et à l’Association française pour la protection de la propriété intellectuelle (AFPPI).

Expérience

  • Verimatrix sells XTD assets to GuardsquareJones Day advised Verimatrix in the sale of the Extended Threat Defense (XTD) technology and assets to Guardsquare.
  • Inflexion sells Aspen Pumps Group to largest ever European Continuation FundJones Day advised Inflexion Private Equity on its sale of Aspen Pumps Group to Inflexion Continuation Fund I, a new continuation fund established by Inflexion to acquire Aspen and three other Inflexion-managed assets.
  • BioMarin pursues litigation against Ascendis Pharma A/S in UPCJones Day represents BioMarin Pharmaceutical, Inc. in patent infringement proceedings against Ascendis Pharma A/S for infringement of European patent EP 3 175 863 B1 at the Unified Patent Court (UPC) in Munich, Germany. The patent covers long-acting variants of C-Type Natriuretic Peptide ("CNP").
  • PERI and Combisafe settle UPC litigation and related patent cases in Germany and FranceJones Day defended PERI SE, a leading manufacturer and supplier of formwork and scaffolding systems and provider of 3D concrete printing, and PERI Vertrieb Deutschland GmbH & Co. KG in patent litigation against Combisafe before the Unified Patent Court, Paris central division, Munich and Düsseldorf District Court, Munich Court of Appeals, German Federal Patent Court, and Paris Court concerning a safety system comprising post-holders.
  • CJ CheilJedang enforces French patent against MetexJones Day represents CJ CheilJedang Corporation, a major Korean-based multinational company, in patent infringement litigation involving genetically engineered microorganisms for the production of certain essential amino acids before the French court.
  • Vibrantz defends patent dispute before Unified Patent Court in MunichJones Day represents Vibrantz GmbH, a manufacturer of specialty chemicals and materials, in patent litigation before the Unified Patent Court, Munich local division, in a dispute over certain precious metal sinter pastes for chip bonding.
  • Ahlström Capital BV and Nidoco AB invest in the Decor business of Ahlstrom-MunksjöJones Day advised Ahlström Capital BV and Nidoco AB in the acquisition of the Decor business of Ahlstrom-Munksjö.
  • Deezer merges with and into I2PO S.A.Jones Day advised Deezer S.A. in the context of the SPAC transaction whereby Deezer S.A. merged with and into I2PO S.A., a French SPAC listed on the professional segment of the regulated market of Euronext Paris and the related PIPE financing.
  • Sanofi announces carve-out creating EUROAPI and spin-off of approximately 58% of shares to its shareholdersJones Day advised Sanofi in the carve out creating EUROAPI (a leading European company dedicated to the development, production and marketing of active pharmaceutical ingredients) and the listing of this entity on Euronext Paris and the placement of 12% to the French State (through French Tech Souveraineté) for a price of up to €150 million.
  • INAO obtains landmark decision in "Saucisson d'Avergne" protected geographical indicationJones Day successfully represented the French Institute of Origin and Quality (INAO) against a large producer of sausages and related products massively commercialized in large national supermarkets in France under the "Louis Auvergne" trademark, while its products could not benefit from the "Saucisson d'Auvergne" protected geographical indication.
  • Omnes Capital, Merieux Equity Partners, and Elaia Partners participate in €20 million financing round of SeqOne GenomicsJones Day advised Omnes Capital, Merieux Equity Partners, and Elaia Partners in the €20 million financing round of SeqOne Genomics, a French-based provider of next genomic analysis solutions for personalized medicine.
  • Elephant participates in €30 million Series B financing round of DataDomeJones Day represented Elephant as lead investor in the €30 million Series B round of financing of DataDome, a French leading bot protection vendor.
  • French biotech company seeks to audit and to improve existing trade secret protection policyJones Day is advising a French biotechnology company with respect to auditing and improving its existing trade secret protection policy.
  • Aurora Resurgence sells Alltub Group to One Equity PartnersJones Day advised Aurora Resurgence in the sale of portfolio company Alltub Group to One Equity Partners.
  • New Alpha participates in €4 million financing round of Fred de la comptaJones Day advised New Alpha Asset Management in connection with the €4 million (US$4.6 million) round of financing of Fred de la compta, a company providing a platform and data analysis tools in the field of accounting.
  • Autres publications

    • 11/2/2025
      French chapter of "Patent Protection for Second Medical Uses", 3rd ed, Kluwer Law
    • 12/3/2024
      UPC Düsseldorf LD, 10x Genomics v. Curio, LinkedIn
    • 10/18/2024
      UPC Düsseldorf LD,Bekaert Binjiang v. Siltronic, LinkedIn
    • 10/11/2024
      Requête aux fins de saisie-contrefaçon sur le fondement d’une demande de brevet : une curieuse application du principe de proportionnalité, Blip Education
    • 10/2/2024
      UPC Nordic-Baltic RD, Imbox Protection AS v. Brunngård, LinkedIn
    • 9/25/2024
      UPC The Hague LD, Data Detection Technologies Ltd v. X, LinkedIn
    • 9/11/2024
      UPC Milan LD, Primetals v. Danieli, LinkedIn
    • 8/26/2024
      UPC Copenhagen LD, Hybridgenerator v HGSystem, LinkedIn
    • 3/15/2024
      Action en interdiction provisoire sur la base d’une demande de brevet : la cour d’appel de Paris enfonce le clou, Blip Education
    • 11/15/2021
      De la possibilité de se « pourvoir au fond, Blip Education

    • April 18, 2024
      AIPPI Trilateral Meeting Panel: Indirect Infringement in Cross-Border Situations